Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
Add more filters











Publication year range
1.
Sci Rep ; 10(1): 15473, 2020 09 23.
Article in English | MEDLINE | ID: mdl-32968084

ABSTRACT

Due to breakthroughs in RNAi and genome editing methods in the past decade, it is now easier than ever to study fine details of protein synthesis in animal models. However, most of our understanding of translation comes from unicellular organisms and cultured mammalian cells. In this study, we demonstrate the feasibility of perturbing protein synthesis in a mouse liver by targeting translation elongation factor 2 (eEF2) with RNAi. We were able to achieve over 90% knockdown efficacy and maintain it for 2 weeks effectively slowing down the rate of translation elongation. As the total protein yield declined, both proteomics and ribosome profiling assays showed robust translational upregulation of ribosomal proteins relative to other proteins. Although all these genes bear the TOP regulatory motif, the branch of the mTOR pathway responsible for translation regulation was not activated. Paradoxically, coordinated translational upregulation of ribosomal proteins only occurred in the liver but not in murine cell culture. Thus, the upregulation of ribosomal transcripts likely occurred via passive mTOR-independent mechanisms. Impaired elongation sequesters ribosomes on mRNA and creates a shortage of free ribosomes. This leads to preferential translation of transcripts with high initiation rates such as ribosomal proteins. Furthermore, severe eEF2 shortage reduces the negative impact of positively charged amino acids frequent in ribosomal proteins on ribosome progression.


Subject(s)
Elongation Factor 2 Kinase/metabolism , Liver/metabolism , RNA, Small Interfering/metabolism , Ribosomal Proteins/metabolism , TOR Serine-Threonine Kinases/metabolism , Animals , Cell Cycle , Female , Gene Knockdown Techniques , Mice , Protein Biosynthesis , Proteome/metabolism , RNA, Messenger/metabolism , Up-Regulation
2.
Bioorg Med Chem Lett ; 29(16): 2229-2235, 2019 08 15.
Article in English | MEDLINE | ID: mdl-31248772

ABSTRACT

Prostate cancer (PC) is the second most commonly occurring cancer in men. Conventional chemotherapy has wide variety of disadvantages such as high systemic toxicity and low selectivity. Targeted drug delivery is a promising approach to decrease side effects of therapy. Prostate specific membrane antigen (PSMA) is overexpressed in prostate cancer cells while low level of expression is observed in normal cells. In this study we describe the development of Glu-urea-Lys based PSMA-targeting conjugates with paclitaxel. A series of new PSMA targeting conjugates with paclitaxel was designed and synthesized. The cytotoxicity of conjugates was evaluated against prostate (LNCaP, 22Rv1 and PC-3) and non-prostate (Hek293T, VA13, A549 and MCF-7) cell lines. The most promising conjugate 21 was examined in vivo using 22Rv1 xenograft mice model. It demonstrated good efficiency comparable with paclitaxel, while reduced toxicity. 3D molecular docking study was also performed to understand underlying mechanism of binding and further optimization of the linker substructure and conjugates structure for improving the target affinity. These conjugates may be useful for further design of novel PSMA targeting delivery systems for PC.


Subject(s)
Drug Delivery Systems/methods , Paclitaxel/chemical synthesis , Prostatic Neoplasms/drug therapy , Animals , Humans , Male , Mice
4.
Bioorg Med Chem Lett ; 29(10): 1246-1255, 2019 05 15.
Article in English | MEDLINE | ID: mdl-30904185

ABSTRACT

Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), has recently emerged as a prominent biomarker of prostate cancer (PC) and as an attractive protein trap for drug targeting. At the present time, several drugs and molecular diagnostic tools conjugated with selective PSMA ligands are actively evaluated in different preclinical and clinical trials. In the current work, we discuss design, synthesis and a preliminary biological evaluation of PSMA-specific small-molecule carrier equipped by Doxorubicin (Dox). We have introduced an unstable azo-linker between Dox and the carrier hence the designed compound does release the active substance inside cancer cells thereby providing a relatively high Dox concentration in nuclei and a relevant cytotoxic effect. In contrast, we have also synthesized a similar conjugate with a stable amide linker and it did not release the drug at all. This compound was predominantly accumulated in cytoplasm and did not cause cell death. Preliminary in vivo evaluation has showed good efficiency for the degradable conjugate against PC3-PIP(PSMA+)-containing xenograft mine. Thus, we have demonstrated that the conjugate can be used as a template to design novel analogues with improved targeting, anticancer activity and lower rate of potential side effects. 3D molecular docking study has also been performed to elucidate the underlying mechanism of binding and to further optimization of the linker area for improving the target affinity.


Subject(s)
Antigens, Surface/chemistry , Antineoplastic Agents/chemical synthesis , Doxorubicin/chemistry , Glutamate Carboxypeptidase II/chemistry , Animals , Antigens, Surface/metabolism , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Binding Sites , Cell Line, Tumor , Cell Nucleus/chemistry , Cell Nucleus/metabolism , Cell Survival/drug effects , Doxorubicin/pharmacology , Glutamate Carboxypeptidase II/metabolism , Humans , Ligands , Male , Mice , Molecular Docking Simulation , Prostatic Neoplasms/drug therapy , Protein Structure, Tertiary , Transplantation, Heterologous
5.
Curr Drug Deliv ; 13(8): 1303-1312, 2016.
Article in English | MEDLINE | ID: mdl-27440073

ABSTRACT

During the past decade asialoglycoprotein receptor (ASGP-R) expressed predominantly by hepatocytes has attracted a considerable attention as a convenient biomolecular trap for targeted drug delivery. Currently, several selective galactose-containing ligands equipped by drug molecules, e.g. known anticancer therapeutics, as well as diagnostic tools are under active preclinical development. In this paper, we have carried out a rational in silico screening among the molecules available in ChemDiv collection and compounds provided by our colleagues to reveal potential ASGP-R binders. Thus, 3D molecular docking approach provided a set of 100 `high score` molecules that was subsequently evaluated in vitro using an advanced Surface Plasmon Resonance (SPR) technique. As a result, dozens of novel small-molecule ASGP-R ligands with high diversity in structure were identified. Several hits showed the binding affinity much more better than that determined for galactose and Nacetylgalactosamine which were used as reference compounds. The disclosed molecules can be reasonably regarded as promising molecular devices for targeted drug delivery to hepatocytes.


Subject(s)
Asialoglycoprotein Receptor/metabolism , Asialoglycoprotein Receptor/chemistry , Computer Simulation , Drug Delivery Systems , Hepatocytes/metabolism , Ligands , Molecular Docking Simulation , Surface Plasmon Resonance
6.
J Drug Target ; 24(8): 679-93, 2016 09.
Article in English | MEDLINE | ID: mdl-26887438

ABSTRACT

Prostate cancer (PC) is the prevalent malignancy widespread among men in the Western World. Prostate specific membrane antigen (PSMA) is an established PC marker and has been considered as a promising biological target for anti-PC drug delivery and diagnostics. The protein was found to be overexpressed in PC cells, including metastatic, and the neovasculature of solid tumors. These properties make PSMA-based approach quite appropriate for effective PC imaging and specific drug therapy. Through the past decade, a variety of PSMA-targeted agents has been systematically evaluated. Small-molecule compounds have several advantages over other classes, such as improved pharmacokinetics and rapid blood clearance. These low-weight ligands have similar structure and can be divided into three basic categories in accordance with the type of their zinc-binding core-head. Several PSMA binders are currently undergoing clinical trials generally for PC imaging. The main goal of the present review is to describe the recent progress achieved within the title field and structure activity relationships (SAR) disclosed for different PSMA ligands. Recent in vitro and in vivo studies for each type of the compounds described have also been briefly summarized.


Subject(s)
Antigens, Surface/metabolism , Drug Carriers/chemistry , Glutamate Carboxypeptidase II/metabolism , Prostatic Neoplasms/drug therapy , Small Molecule Libraries/chemistry , Binding Sites , Drug Carriers/pharmacokinetics , Humans , Ligands , Male , Molecular Structure , Molecular Targeted Therapy , Prostatic Neoplasms/metabolism , Protein Binding , Small Molecule Libraries/pharmacokinetics , Structure-Activity Relationship
7.
Bioorg Med Chem ; 24(4): 802-11, 2016 Feb 15.
Article in English | MEDLINE | ID: mdl-26780833

ABSTRACT

A set of novel selenohydantoins were synthesized via a convenient and versatile approach involving the reaction of isoselenocyanates with various amines. We also revealed an unexpected Z→E isomerization of pyridin-2-yl-substituted selenohydantoins in the presence of Cu(2+) cations. The detailed mechanism of this transformation was suggested on the basis of quantum-chemical calculations, and the key role of Cu(2+) was elucidated. The obtained compounds were subsequently evaluated against a panel of different cancer cell lines. As a result, several molecules were identified as promising micromolar hits with good selectivity index. Instead of analogous thiohydantoins, which have been synthesized previously, selenohydantoins demonstrated a relatively high antioxidant activity comparable (or greater) to the reference molecule, Ebselen, a clinically approved drug candidate. The most active compounds have been selected for further biological trials.


Subject(s)
Antineoplastic Agents/chemical synthesis , Antioxidants/chemical synthesis , Hydantoins/chemical synthesis , Organoselenium Compounds/chemical synthesis , Antineoplastic Agents/pharmacology , Antioxidants/pharmacology , Azoles/pharmacology , Cell Line, Tumor , Cell Survival/drug effects , Copper/chemistry , Cyanates/chemistry , Drug Screening Assays, Antitumor , Glutathione Peroxidase/antagonists & inhibitors , Glutathione Peroxidase/chemistry , Humans , Hydantoins/pharmacology , Inhibitory Concentration 50 , Isoindoles , Organoselenium Compounds/pharmacology , Pyridines/chemistry , Quantum Theory , Stereoisomerism , Structure-Activity Relationship
8.
Curr Top Med Chem ; 16(12): 1372-82, 2016.
Article in English | MEDLINE | ID: mdl-26585933

ABSTRACT

Non-structural 5A (NS5A) protein plays a crucial role in the replication of hepatitis C virus (HCV) and during the past decade has attracted increasing attention as a promising biological target for the treatment of viral infections and related disorders. Small-molecule NS5A inhibitors have shown significant antiviral activity in vitro and in vivo. Several lead molecules are reasonably regarded as novel highly potent drug candidates with favorable ADME features and tolerable side effects. The first-in-class daclatasvir has recently been launched into the market and 14 novel molecules are currently under evaluation in clinical trials. From this perspective, we provide an overview of the available chemical space of small-molecule NS5A inhibitors and their PK properties, mainly focusing on the diversity in structure and scaffold representation.


Subject(s)
Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Hepacivirus/drug effects , Small Molecule Libraries/chemistry , Small Molecule Libraries/pharmacology , Viral Nonstructural Proteins/antagonists & inhibitors , Animals , Antiviral Agents/chemical synthesis , Hepacivirus/metabolism , Humans , Microbial Sensitivity Tests , Molecular Conformation , Small Molecule Libraries/chemical synthesis , Virus Replication/drug effects
9.
J Mol Biol ; 428(10 Pt B): 2134-45, 2016 05 22.
Article in English | MEDLINE | ID: mdl-26707202

ABSTRACT

N6-methyladenosine (m(6)A) is ubiquitously present in the RNA of living organisms from Escherichia coli to humans. Methyltransferases that catalyze adenosine methylation are drastically different in specificity from modification of single residues in bacterial ribosomal or transfer RNA to modification of thousands of residues spread among eukaryotic mRNA. Interactions that are formed by m(6)A residues range from RNA-RNA tertiary contacts to RNA-protein recognition. Consequences of the modification loss might vary from nearly negligible to complete reprogramming of regulatory pathways and lethality. In this review, we summarized current knowledge on enzymes that introduce m(6)A modification, ways to detect m(6)A presence in RNA and the functional role of this modification everywhere it is present, from bacteria to humans.


Subject(s)
Adenosine/analogs & derivatives , Adenosine/metabolism , Escherichia coli/metabolism , RNA/metabolism , Humans , Methylation , Methyltransferases/metabolism
10.
Curr Top Med Chem ; 16(12): 1383-91, 2016.
Article in English | MEDLINE | ID: mdl-26585932

ABSTRACT

In recent years, nonstructural protein 5A (NS5A) has rapidly emerged as a promising therapeutic target for Hepatitis C (HCV) virus therapy. It is involved in both viral RNA replication and virus assembly and NS5A plays a critical role in the regulation of HCV life cycle. NS5A replication complex inhibitors (NS5A RCIs) have demonstrated strong antiviral activity in vitro and in vivo. However, wild-type resistance mutations and a wide range of genotypes significantly reduce their clinical efficacy. The exact mechanism of NS5A action still remains elusive, therefore several in silico models have been constructed to gain insight into the drug binding and subsequent structural optimization to overcome resistance. This paper provides a comprehensive overview of the computational studies towards NS5A mechanism of action and the design of novel small-molecule inhibitors.


Subject(s)
Antiviral Agents/pharmacology , Computer Simulation , Drug Design , Hepacivirus/drug effects , Small Molecule Libraries/pharmacology , Viral Nonstructural Proteins/antagonists & inhibitors , Animals , Antiviral Agents/chemical synthesis , Antiviral Agents/chemistry , Humans , Microbial Sensitivity Tests , Models, Molecular , Molecular Conformation , Small Molecule Libraries/chemical synthesis , Small Molecule Libraries/chemistry , Virus Replication/drug effects
11.
Am J Respir Crit Care Med ; 169(1): 97-104, 2004 Jan 01.
Article in English | MEDLINE | ID: mdl-14578216

ABSTRACT

The integrin alpha1beta1 (very late antigen-1; CD49a/CD29) is a major adhesion receptor for collagen I, IV, and VI, and its induced expression on activated monocytes and lymphocytes plays a central role in their retention and activation at inflammatory sites in autoimmune pathologies. However, the role of alpha1beta1 in allergic settings has not been explored. In this study, we show that a single 45-mg dose of aerosolized monoclonal antibody AQC2 to the alpha1 chain of human and sheep very late antigen-1, given 30 minutes before challenge, blocks both the allergen-induced late response and the associated airway hyperresponsiveness, functional indicators of allergen-induced inflammation, in sheep. AQC2 does not affect the early response. Consistent with these effects, AQC2 tended to reduce the cell response associated with local antigen instillation. An isotype-matched control antibody had no protective effects. Two humanized versions of AQC2, a wild-type IgG1 and an aglycosyl form of the same monoclonal antibody, which has reduced Fc receptor-mediated effector functions, are equally effective in blocking the antigen-induced late response and airway hyperresponsiveness in the sheep model. These data suggest that mononuclear leukocyte adhesion-dependent pathologies contribute to allergic lung disease and provide proof-of-concept that antagonists of alpha1 integrins may be useful in preventing these events.


Subject(s)
Antibodies, Monoclonal/pharmacology , Bronchial Hyperreactivity/immunology , Bronchial Hyperreactivity/prevention & control , Integrins/antagonists & inhibitors , Receptors, Very Late Antigen/immunology , Administration, Inhalation , Airway Resistance/drug effects , Animals , Bronchial Provocation Tests , Disease Models, Animal , Female , Integrins/physiology , Male , Probability , Reference Values , Sensitivity and Specificity , Sheep, Domestic
12.
J Immunol ; 171(6): 2804-11, 2003 Sep 15.
Article in English | MEDLINE | ID: mdl-12960301

ABSTRACT

Adhesive interactions are crucial to cell migration into inflammatory sites. Using murine lymphocytic choriomeningitis virus as an Ag model system, we have investigated expression and function of collagen-binding integrins, alpha(1)beta(1) and alpha(2)beta(1), on activated and memory T cells. Using this system and MHC tetramers to define Ag-specific T cells, we demonstrate that contrary to being VLAs, expression of alpha(1)beta(1) and alpha(2)beta(1) can be rapidly induced on acutely activated T cells, that expression of alpha(1)beta(1) remains elevated on memory T cells, and that expression of alpha(1)beta(1) parallels that of viral-specific effector CD8(+) T cells (defined by tetramer and IFN-gamma staining). In an adoptive transfer model, mAb-mediated blockade of these integrins on activated effector and memory T cells inhibited Ag-specific delayed-type hypersensitivity responses; similar decreased responses were seen upon transfer of alpha(1)-deficient activated/memory T cells. Thus, expression of alpha(1)beta(1) and alpha(2)beta(1) integrins on activated T cells is directly functionally important for generation of inflammatory responses within tissues. Finally, the inhibitory effect of alpha(1)beta(1) blockade on the delayed-type hypersensitivity response could be bypassed by direct injection of Ag-specific T cells to inflammatory sites, demonstrating for the first time in vivo that collagen-binding integrins are involved in leukocyte migration into tissues.


Subject(s)
Collagen/metabolism , Integrin alpha1beta1/biosynthesis , Integrin alpha1beta1/physiology , Integrin alpha2beta1/biosynthesis , Integrin alpha2beta1/physiology , Lymphocyte Activation/immunology , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/virology , Adoptive Transfer , Animals , Antigens, Viral/immunology , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/virology , Epitopes, T-Lymphocyte/immunology , Female , Hindlimb , Immunophenotyping , Injections, Subcutaneous , Integrin alpha1beta1/antagonists & inhibitors , Integrin alpha1beta1/genetics , Integrin alpha2beta1/antagonists & inhibitors , Integrin alpha2beta1/metabolism , Kinetics , Lymphocyte Activation/genetics , Lymphocytic Choriomeningitis/genetics , Lymphocytic Choriomeningitis/immunology , Lymphocytic Choriomeningitis/metabolism , Lymphocytic choriomeningitis virus/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Protein Binding , Spleen/cytology , Spleen/immunology , Spleen/transplantation , T-Lymphocyte Subsets/metabolism
13.
Dev Biol ; 261(2): 520-36, 2003 Sep 15.
Article in English | MEDLINE | ID: mdl-14499657

ABSTRACT

In vertebrates, the nervous system arises from a flat sheet of epithelial cells, the neural plate, that gradually transforms into a hollow neural tube. This process, called neurulation, involves sequential changes in cellular interactions that are precisely coordinated both spatially and temporally by the combined actions of morphogens. To gain further insight into the molecular events regulating cell adhesion during neurulation, we investigated whether the adhesive and migratory capacities of neuroepithelial cells might be modulated by Sonic hedgehog (Shh), a signaling molecule involved in the control of cell differentiation in the ventral neural tube. When deposited onto extracellular matrix components in vitro, neural plates explanted from avian embryos at early neurulation readily dispersed into monolayers of spread cells, thereby revealing their intrinsic ability to migrate. In the presence of Shh added in solution to the culture medium, the explants still exhibited the same propensity to disperse. In contrast, when Shh was immobilized to the substrate or produced by neuroepithelial cells themselves after transfection, neural plate explants failed to disperse and instead formed compact structures. Changes in the adhesive capacities of neuroepithelial cells caused by Shh could be accounted for by inactivation of surface beta1-integrins combined with an increase in N-cadherin-mediated cell adhesion. Furthermore, immobilized Shh promoted differentiation of neuroepithelial cells into motor neurons and floor plate cells with the same potency as soluble Shh. However, the effect of Shh on the neuroepithelial cell adhesion was discernible and apparently independent from its differentiation effect and was not mediated by the signaling cascade elicited by the Patched-Smoothened receptor and involving the Gli transcription factors. Thus, our experiments indicate that Shh is able to control sequentially adhesion and differentiation of neuroepithelial cells through different mechanisms, leading to a coordinated regulation of the various cell interactions essential for neural tube morphogenesis.


Subject(s)
Cell Differentiation/physiology , Coturnix/embryology , Nervous System/embryology , Trans-Activators/metabolism , Animals , Cell Adhesion/physiology , Epithelium/metabolism , Hedgehog Proteins , In Vitro Techniques
14.
J Invest Dermatol ; 120(6): 1100-9, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12787141

ABSTRACT

Angiogenesis requires endothelial cell survival and proliferation, which depend upon cytokine stimulation together with integrin-mediated cell adhesion to extracellular matrix; however, the question of which specific integrins are the best targets for suppressing neovascularization is controversial and unresolved. Therefore, we designed experiments to compare contributions of individual integrins from both the alphav and beta1 integrin subfamilies. With immobilized antibodies, we determined that adhesion through integrins alpha1beta1, alpha2beta1, alphavbeta3, and alphavbeta5 each individually supported dermal microvascular endothelial cell survival. Also, substratum coated with collagen I (which binds alpha1beta1 and alpha2beta1) and vitronectin (which binds alphavbeta3 and alphavbeta5) each supported survival. Importantly, substratum coated with combinations of collagen I and vitronectin were most effective at promoting survival, and survival on three-dimensional collagen I gels was strongly enhanced by vitronectin. Vascular endothelial growth factor activation of the p44/p42 mitogen-activated protein kinase pathway, which is required for angiogenesis, was supported by adhesion through either alpha1beta1, alpha2beta1, alphavbeta3, or alphavbeta5, and pharmacologic inhibition of this pathway blocked proliferation and suppressed survival. Therefore, these studies establish that the alpha1beta1, alpha2beta1, alphavbeta3, and alphavbeta5 integrins each support dermal microvascular endothelial cell viability, and that each collaborate with vascular endothelial growth factor to support robust activation of the mitogen-activated protein kinase pathway which mediates both proliferation and survival. Moreover, survival is supported most significantly by extracellular matrices, which engage all of these integrins in combination. Consistent with important complementary and overlapping functions, combined antagonism of these integrins provided superior inhibition of angiogenesis in skin, indicating that multiplicity of integrin involvement should be considered in designing strategies for controlling neovascularization.


Subject(s)
Integrin alphaV/physiology , Integrin beta1/physiology , Neovascularization, Physiologic/physiology , Skin/blood supply , Animals , Cell Line , Cell Survival/physiology , Collagen Type I/physiology , Drug Combinations , Endothelial Growth Factors/physiology , Endothelium, Vascular/physiology , Enzyme Activation , Humans , Integrin alpha1beta1/physiology , Integrin alpha2beta1/physiology , Integrin alphaVbeta3/physiology , Integrins/physiology , Intercellular Signaling Peptides and Proteins/physiology , Lymphokines/physiology , Microcirculation , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3 , Mitogen-Activated Protein Kinases/metabolism , Receptors, Vitronectin/physiology , Spodoptera , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors , Vitronectin/physiology
15.
Mol Biol Cell ; 14(6): 2327-41, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12808033

ABSTRACT

During hepatic wound healing, activation of key effectors of the wounding response known as stellate cells leads to a multitude of pathological processes, including increased production of endothelin-1 (ET-1). This latter process has been linked to enhanced expression of endothelin-converting enzyme-1 (ECE-1, the enzyme that converts precursor ET-1 to the mature peptide) in activated stellate cells. Herein, we demonstrate up-regulation of 56- and 62-kDa ECE-1 3'-untranslated region (UTR) mRNA binding proteins in stellate cells after liver injury and stellate cell activation. Binding of these proteins was localized to a CC-rich region in the proximal ECE-1 3' UTR base pairs (the 56-kDa protein) and to a region between 60 and 193 base pairs in the ECE-1 3' UTR mRNA (62 kDa). A functional role for the 3' UTR mRNA/protein interaction was established in a series of reporter assays. Additionally, transforming growth factor-beta1, a cytokine integral to wound healing, stimulated ET-1 production. This effect was due to ECE-1 mRNA stabilization and increased ECE-1 expression in stellate cells, which in turn was a result of de novo synthesis of the identified 56- and 62-kDa ECE-1 3' UTR mRNA binding proteins. These data indicate that liver injury and the hepatic wound healing response lead to ECE-1 mRNA stabilization in stellate cells via binding of 56- and 62-kDa proteins, which in turn are regulated by transforming growth factor-beta. The possibility that the same or similar regulatory events are present in other forms of wound healing is raised.


Subject(s)
Endothelin-1/metabolism , Liver/injuries , RNA-Binding Proteins/metabolism , Wound Healing/physiology , 3' Untranslated Regions , Aspartic Acid Endopeptidases/biosynthesis , Aspartic Acid Endopeptidases/genetics , Binding Sites , Endothelin-Converting Enzymes , Liver/metabolism , Metalloendopeptidases , RNA, Messenger/metabolism
16.
J Vasc Res ; 40(1): 37-46, 2003.
Article in English | MEDLINE | ID: mdl-12644724

ABSTRACT

Constrictive remodeling has been identified as a major contributor to restenosis following angioplasty. Characterization of transforming growth factor-beta (TGF-beta)-mediated cellular events in the adventitia and their contribution to vascular remodeling, however, has not previously been studied in detail. The balloon catheter denudation model was performed on rat carotid artery, and groups of rats were treated with vehicle or a TGF-beta inhibitor, a soluble TGF-beta receptor type II (TGF-beta R:Fc). Adventitial cell proliferation, which peaked 4 days after injury, was characterized by the de novo formation of several cell layers surrounding the outer adventitia and this process was not dependent upon TGF-beta activity. These neoadventitial cells expressed an abundance of collagen type I and a fetal isoform of fibronectin containing the EIIIA domain, and the expression of both proteins was suppressed in the presence of TGF-beta R:Fc. Lumenal narrowing was apparent 14 days after injury. Inhibition of TGF-beta signaling promoted vessel enlargement. As a result, lumen size did not change despite neointima formation. In conclusion, adventitial fibrosis with abundant collagen matrix deposition but not adventitial cell proliferation is dependent upon endogenous TGF-beta activity. Furthermore, inhibition of TGF-beta signaling prevents injury-induced reduction in lumen area by promoting vessel enlargement.


Subject(s)
Arteries/injuries , Transforming Growth Factor beta/physiology , Vascular Diseases/etiology , Animals , Arteries/chemistry , Arteries/pathology , Carotid Arteries/chemistry , Carotid Arteries/pathology , Catheterization , Cell Division , Collagen Type I/analysis , Fibronectins/analysis , Fibrosis , Proteoglycans/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Transforming Growth Factor beta , Transforming Growth Factor beta/antagonists & inhibitors
17.
J Clin Invest ; 110(12): 1773-82, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12488427

ABSTRACT

Central to inflammatory responses are the integrin-mediated adhesive interactions of cells with their ECM-rich environment. We investigated the role of the collagen-binding integrin alpha(1)beta(1) in intestinal inflammation using the mouse model of colitis induced by dextran sodium sulfate (DSS). mAb's directed against murine alpha(1) were found to significantly attenuate inflammation and injury in DSS-treated wild-type mice; similar protection was seen in mice deficient for alpha(1)beta(1) integrin. Blockade or loss of alpha(1)beta(1) was also associated with decreased mucosal inflammatory cell infiltrate and cytokine production. Importantly, we demonstrated that development and alpha(1)-mediated inhibition of DSS-induced colitis occurred independently of lymphocytes (Rag-2(-/-) mice), and identified the monocyte as a key alpha(1)beta(1)-expressing cell type involved in the development of colitis in this model. In response to DSS, both alpha(1) deficiency and anti-alpha(1) mAb treatment significantly reduced monocyte accumulation and activation within the lamina propria. In summary, the data demonstrate that engagement of leukocyte-associated alpha(1)beta(1) receptors with ECM plays a pivotal role in mediating intestinal inflammation via promotion of monocyte movement and/or activation within the inflamed interstitium. Therapeutic strategies designed to disrupt such interactions may prove beneficial in treating intestinal inflammation.


Subject(s)
Colitis/metabolism , Collagen/metabolism , Integrin alpha1beta1/metabolism , Intestinal Mucosa/metabolism , Intestines/pathology , Animals , Antibodies, Monoclonal/metabolism , CD11b Antigen/metabolism , Colitis/chemically induced , Colitis/immunology , Colitis/pathology , Cytokines/genetics , Cytokines/metabolism , DNA-Binding Proteins/genetics , Dextran Sulfate/administration & dosage , Dextran Sulfate/toxicity , Disease Models, Animal , Humans , Immunohistochemistry , Indicators and Reagents/toxicity , Integrin alpha1beta1/genetics , Integrin alpha1beta1/immunology , Intestines/immunology , Lymphocytes/metabolism , Male , Mice , Mice, Inbred BALB C , Mice, Knockout , Monocytes/metabolism , Nuclear Proteins , Peroxidase/metabolism , Protein Binding
18.
Immunity ; 17(6): 769-80, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12479823

ABSTRACT

Inflammation occurs in the context of integrin-mediated adhesive interactions of cells with their extracellular matrix environment. We investigated the role of the collagen binding integrin alpha1beta1 in a model of colitis. alpha1beta1 was expressed on lamina propria T cells and monocytes during disease. Both alpha1 deficiency and anti-alpha1 mAb treatment (prophylactic and therapeutic) protected against colitis. In vivo alpha1beta1 blockade improved macroscopic and histologic scores, decreased inflammatory cytokine production, and profoundly affected the ability of lamina propria mononuclear cells to proliferate and produce IFN-gamma in vitro. Development and alpha1-mediated inhibition of colitis can be lymphocyte independent, suggesting that activated monocytes also represent a key alpha1beta1-expressing cell type involved in colitis. These results underscore the importance of innate immunity and, specifically, of leukocyte/matrix interactions in regulating local inflammatory responses.


Subject(s)
Colitis/immunology , Immunity, Innate , Integrin alpha1beta1/immunology , Animals , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/therapeutic use , Colitis/chemically induced , Colitis/drug therapy , Collagen/immunology , Extracellular Matrix/immunology , Female , Mice , Mice, Inbred BALB C , Mice, SCID , Monocytes/immunology , T-Lymphocytes/immunology , Trinitrobenzenesulfonic Acid/toxicity
19.
Int J Cancer ; 102(5): 453-62, 2002 Dec 10.
Article in English | MEDLINE | ID: mdl-12432546

ABSTRACT

A high tumor interstitial fluid pressure (TIFP) is a pathologic characteristic distinguishing the stroma of carcinomas from normal interstitial loose connective tissues. The role of TGF-beta1 and -beta3 in generating a high TIFP was investigated in xenografted experimental anaplastic thyroid carcinoma (ATC) derived from the human ATC cell line KAT-4. A single intravenous injection of a soluble recombinant TGF-beta receptor type II-murine Fc:IgG(2A) chimeric protein that specifically inhibits TGF-beta1 and -beta3, significantly lowered TIFP in a time and concentration dependent manner but did not change total tissue water content in the tumors. Tumor growth rate was higher in tumors treated with the TGF-beta1 and -beta3 inhibitor compared to control tumors during the first 10 days after administration of the inhibitor. The apoptotic index of carcinoma cells, and expression of the cell cycle inhibitor p27(Kip1), were, however, increased in TGF-beta1 and -beta3 inhibitor-treated tumors. Prolonged treatment periods and administration of a second dose of the inhibitor decreased tumor growth rate. The TGF-beta1 and -beta3 inhibitor did not affect proliferation or expression of phosphorylated Smad2 protein in KAT-4 cells cultured in vitro. Our results indicate that members of the TGF-beta family are potential targets for novel anti-cancer treatment directed to the stroma. First by controlling TIFP and by that potentially the uptake of anticancer drugs into tumors and second by their suggested role in maintaining a supportive tumor stroma.


Subject(s)
Carcinoma/metabolism , Extracellular Space/physiology , Thyroid Neoplasms/metabolism , Transforming Growth Factor beta/metabolism , Animals , Apoptosis , Carcinoma/pathology , Cell Cycle Proteins/metabolism , Cell Division , Cyclin-Dependent Kinase Inhibitor p27 , Humans , Mice , Neoplasm Transplantation , Pressure , Protein Serine-Threonine Kinases , Receptor, Transforming Growth Factor-beta Type II , Receptors, Transforming Growth Factor beta , Recombinant Fusion Proteins , Stromal Cells/metabolism , Thyroid Neoplasms/pathology , Transforming Growth Factor beta1 , Transforming Growth Factor beta3 , Transplantation, Heterologous , Tumor Cells, Cultured , Tumor Suppressor Proteins/metabolism
20.
Immunol Rev ; 186: 208-20, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12234373

ABSTRACT

By binding to extracellular matrix (ECM) proteins, integrins integrate signals from outside the cell and transmit them inwards, thereby providing cells with information about location and allowing them to respond to stimuli in a manner appropriate to their environment. This is particularly important for monocytes and macrophages, given their wide distribution throughout the body and the vital role they play in immune and inflammatory responses. Integrin-mediated interaction of monocytes with ECM is a potent regulator of gene expression and is strongly synergized by the presence of growth factors. This synergy between growth factors and integrins is also apparent in the overlap seen in their signaling pathways. Integrin-mediated interaction with ECM results in increased expression of numerous inflammatory and immune response genes, revealing an important role for ECM-integrin interaction in affecting monocyte function and thus impacting on the development of pathologies. This is of particular relevance in the context of immune and inflammatory responses, where integrin-mediated adhesive interactions with the ECM-rich peripheral tissues are central to the localization of both resident and infiltrating monocytes at inflammatory sites. Here, we will review the functional effects of integrin-ECM interactions on monocytes, with particular attention to the regulation of gene expression by ECM and its functional implications.


Subject(s)
Extracellular Matrix/physiology , Gene Expression Regulation , Integrins/metabolism , Monocytes/metabolism , Animals , Humans , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL